Fact CheckerSign in

NCT07094776Enrolling by invitation

Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study

Source: ClinicalTrials.gov · Last updated 6 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Purpose of the Study: This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS). MG53 is involved in cell membrane repair and may play a role in insulin resistance, which is common in PCOS. Study Procedures: Women between 18 and 45 years of age will be invited to participate. The study population will include both women diagnosed with PCOS and healthy controls. A single blood sample (approximately 5 mL) will be collected from each participant. MG53 levels will be measured using an ELISA laboratory assay. Significance of the Study: Analysis of MG53 levels in relation to hormonal and metabolic markers may help determine whether MG53 is associated with insulin resistance and other characteristics of PCOS.

Status (registry)
Enrolling by invitation
Study type
Observational
Enrollment
128 (estimated)
First submitted
23 Jul 2025
Start date
Jun 2025
Primary completion date
Aug 2025
Lead sponsor
Havva Betül Bacak
NCT number
NCT07094776

What you commit to

  • Study type: Observational
  • Planned participants: 128
  • From Jun 2025 to the primary completion date, Aug 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Presence of chronic systemic disease

Other

  • Currently pregnant
  • Use of metformin or any hormonal treatment

Who the study is looking for

  • Female participants aged 18 to 45 years
  • Diagnosed with polycystic ovary syndrome (PCOS) according to Rotterdam criteria or healthy controls without PCOS
  • Able and willing to provide informed consent

Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Health Sciences, Gaziosmanpaşa Training and Research Hospital
Coordinator of this site? Confirm its status
GaziosmanpaşaTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.